Live
BioPharma DiveGeneric drugmakers gain key victory in ‘skinny label’ patent caseEndpoints NewsInnovent declares Phase 3 success for ADC that attracted huge Takeda dealFierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionClinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral InfectionsFierceBiotechInsulet debuts latest enhancements to popular Omnipod insulin delivery systemPharmaVoiceBMS under pressure in schizophrenia; Summit/Akeso on a winning streakPromega BlogMeasuring What Matters in Metabolic Research: A Bioluminescent ToolkitBioWorldNME Digest: Q1 2026FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranBioWorldNew York University identifies new analogues of mannose-6-phosphateBioWorldAvelos Therapeutics synthesizes new PARG inhibitorsBioWorldSimcere Zaiming Pharmaceutical discovers new MAPK inhibitors
PLoS Biology 19 mars 2026

Distinct Cdc42 protein levels differentially regulate polarized growth and cell fusion in <i>Schizosaccharomyces pombe</i>

Distinct Cdc42 protein levels differentially regulate polarized growth and cell fusion in Schizosaccharomyces pombe

Original
Contenu indisponible. Consultez la source originale.